Cara Therapeutics Company Profile (NASDAQ:CARA)

About Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics logoCara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CARA
  • CUSIP: N/A
  • Web:
  • Market Cap: $508.42 million
  • Outstanding Shares: 32,507,000
Average Prices:
  • 50 Day Moving Avg: $17.60
  • 200 Day Moving Avg: $16.09
  • 52 Week Range: $4.92 - $28.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.31
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $990,000.00
  • Price / Sales: 507.63
  • Book Value: $0.90 per share
  • Price / Book: 17.18
  • EBIDTA: ($68,880,000.00)
  • Return on Equity: -117.41%
  • Return on Assets: -98.52%
  • Current Ratio: 3.28%
  • Quick Ratio: 3.28%
  • Average Volume: 2.73 million shs.
  • Beta: 3.17
  • Short Ratio: 16.25

Frequently Asked Questions for Cara Therapeutics (NASDAQ:CARA)

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.73) by $0.08. The business had revenue of $0.91 million for the quarter, compared to the consensus estimate of $0.11 million. The firm's revenue for the quarter was up 12900.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.39) earnings per share. View Cara Therapeutics' Earnings History.

When will Cara Therapeutics make its next earnings announcement?

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Cara Therapeutics.

Where is Cara Therapeutics' stock going? Where will Cara Therapeutics' stock price be in 2017?

11 brokers have issued twelve-month price targets for Cara Therapeutics' stock. Their forecasts range from $20.00 to $34.00. On average, they expect Cara Therapeutics' share price to reach $27.25 in the next twelve months. View Analyst Ratings for Cara Therapeutics.

What are analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:

  • 1. Needham & Company LLC analysts commented, "Cara announced outcome of planned CR845 Phase 2/3 post-surgical pain trial interim power assessment today. We spoke w/ mgmt for an update. No changes will be made to current randomization ratio across the 3 arms (1:1:1 placebo, 0.5 ug/kg, 1.0ug/kg), however target enrollment will be increased from 125/ arm to 150/ arm. Other pre-specified options were ending trial early due to low probability of success or shifting enrollment to one optimal dose. We view outcome favorably, noting that the two dose arms were evaluated independently by Data Monitoring Cmtee. Implication is that both low and high dose CR845 have potential for statistically significant effect in view of DMC. We had been concerned that low and possibly high dose evaluated in this trial may not be sufficiently high for efficacy. Mgmt guided for completing enrollment for final analysis by YE17. Separately, top-line results from CR845 Phase 2b trial in Osteoarthritis are expected later this month. We are favorably inclined based on encouraging trends in an 80-pt 2wk Phase 2a trial, but acknowledge risks tied to absence of placebo arm." (6/21/2017)
  • 2. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (5/10/2017)
  • 3. HC Wainwright analysts commented, "CR845 as safe as placebo in respiratory safety Phase 1. Cara announced positive data this morning from a 15-patient Phase 1 trial in healthy volunteers designed to formally test for IV ‘845’s impact on respiratory drive, as respiratory depression remains one of the more severe, and potentially life-threatening, side effects of mu opioids, which ‘845 is not. The trial was a three-way crossover design utilizing the expected therapeutic dose of 1.0 ug/kg, as well as a 5.0 ug/kg supratherapeutic dose to test the upper bounds for safety. Patient respiratory drive was measured via end-tidal CO2 (ETCO2), oxygen saturation (SpO2), and respiratory rate, with primary endpoints focused on the former two. ETCO2 ranged from 36.1 to 37.8 mmHg prior to dosing, and remained well below the endpoint threshold of a 10mmHg sustained increase in ETCO2, with values of 38.1, 38.1, and 38.3 mmHg for the placebo, 1.0 ug/kg, and 5.0 ug/kg doses, respectively, one hour after administration. Both doses of ‘845 also hit on the SpO2 primary endpoint (needed to show SpO2 which did not consistently fall below 92%), with pre-treatment levels ranging from 98.3% to 98.9%, finishing an hour later at 97.8%, 98.2%, and 97.9% for the placebo,1.0 ug/kg, and 5.0 ug/kg doses, respectively. While these two primary endpoints only measured through an hour after treatment, no significant differences were seen on all three measures of respiratory drive throughout the entire 4-hour observation period of the study." (4/24/2017)
  • 4. Cantor Fitzgerald analysts commented, "The Phase 1 safety trial of IV CR845 showed no significant differences in respiratory drive vs. placebo at super-therapeutic dosing levels." (4/24/2017)
  • 5. Piper Jaffray Companies analysts commented, "Today Cara reported positive results from Part A of its Phase II/III trial for IV CR845 in uremic pruritus (UP). In our view, these results are compelling in terms of impact on worst itching scores together with more global measures of quality of life within the context of an 8-week study, as well as safety/tolerability at the go-forward doses of 0.5mcg/kg and 1.0mcg/kg. We see the robust efficacy vs safety data from this Phase II as reducing clinical risk for a broader pivotal program planned to begin by YE17. And beyond the Phase III program, we see this dataset as potentially reducing regulatory and commercial risk, and enhancing value of this asset, in the longer-term. In advance of further clinical progress in UP, including an EOP2 and Phase III start yet in '17, as well as chronic pain and post-op pain updates during 2Q17, we reiterate OW on Cara." (3/28/2017)

Who are some of Cara Therapeutics' key competitors?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the folowing people:

  • Derek T. Chalmers Ph.D., President, Chief Executive Officer, Director
  • Josef C. Schoell CPA, Chief Financial Officer
  • Frederique Menzaghi Ph.D., Vice President, Research & Development
  • Joseph William Stauffer, Chief Medical Officer
  • Harrison M. Bains Jr., Independent Director
  • Jeffrey L. Ives Ph.D., Independent Director
  • Dean Slagel, Independent Director
  • Martin A. Vogelbaum, Independent Director

Who owns Cara Therapeutics stock?

Cara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baldwin Brothers Inc. MA (0.07%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi, Josef Schoell, Michael E Lewis and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.

How do I buy Cara Therapeutics stock?

Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of Cara Therapeutics stock can currently be purchased for approximately $15.46.

MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  410
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $27.25 (76.26% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/5/2017Canaccord GenuityReiterated RatingPositiveHighView Rating Details
7/1/2017Piper Jaffray CompaniesReiterated RatingBuy$27.00HighView Rating Details
6/30/2017Needham & Company LLCReiterated RatingBuy$23.00LowView Rating Details
6/30/2017HC WainwrightReiterated RatingBuy$30.00LowView Rating Details
6/30/2017LaidlawLower Price TargetBuy$35.00 -> $30.00HighView Rating Details
6/30/2017Stifel NicolausReiterated RatingBuy -> Buy$24.00 -> $20.00HighView Rating Details
6/30/2017Janney Montgomery ScottDowngradeBuy -> Neutral$22.00 -> $21.00HighView Rating Details
5/19/2017Cantor FitzgeraldReiterated RatingOverweight$29.00LowView Rating Details
5/15/2017ScotiabankBoost Price TargetOutperform$33.00 -> $34.00N/AView Rating Details
5/15/2017Royal Bank Of CanadaLower Price TargetOutperform$32.00 -> $31.00N/AView Rating Details
5/15/2017Raymond James Financial, Inc.Lower Price TargetMarket Perform$30.00 -> $28.00N/AView Rating Details
5/15/2017CIBCBoost Price Target$28.00 -> $29.00N/AView Rating Details
(Data available from 7/21/2015 forward)


Earnings History for Cara Therapeutics (NASDAQ:CARA)
Earnings by Quarter for Cara Therapeutics (NASDAQ:CARA)
Earnings History by Quarter for Cara Therapeutics (NASDAQ CARA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.73)($0.81)$0.11 million$0.91 millionViewListenView Earnings Details
11/3/2016Q3($0.47)($0.42)$0.09 millionViewN/AView Earnings Details
8/4/2016Q216($0.42)($0.48)$0.13 million$0.08 millionViewN/AView Earnings Details
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.25)$0.50 million$0.87 millionViewListenView Earnings Details
5/12/2015Q415($0.22)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details
3/26/2015Q4($0.28)($0.18)$1.00 million$0.91 millionViewListenView Earnings Details
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details
3/27/2014($0.18)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cara Therapeutics (NASDAQ:CARA)
Current Year EPS Consensus Estimate: $-2.54 EPS
Next Year EPS Consensus Estimate: $-2.45 EPS


Dividend History for Cara Therapeutics (NASDAQ:CARA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cara Therapeutics (NASDAQ:CARA)
Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 52.91%
Insider Trades by Quarter for Cara Therapeutics (NASDAQ:CARA)
Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)
Insider Trades by Quarter for Cara Therapeutics (NASDAQ:CARA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/14/2017Derek T ChalmersCEOSell25,000$15.05$376,250.00View SEC Filing  
7/14/2017Frederique Ph.D. MenzaghiVPSell3,000$15.00$45,000.00View SEC Filing  
6/29/2017Dean SlagelDirectorSell250,000$25.87$6,467,500.00View SEC Filing  
3/31/2017Ventures Vi Lp RhoMajor ShareholderBuy500,000$18.19$9,095,000.00View SEC Filing  
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00View SEC Filing  
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00View SEC Filing  
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66View SEC Filing  
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.00View SEC Filing  
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00View SEC Filing  
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00View SEC Filing  
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00View SEC Filing  
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00View SEC Filing  
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.00View SEC Filing  
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cara Therapeutics (NASDAQ:CARA)
Latest Headlines for Cara Therapeutics (NASDAQ:CARA)
DateHeadline logoFrederique Ph.D. Menzaghi Sells 3,000 Shares of Cara Therapeutics, Inc. (CARA) Stock - July 18 at 7:53 PM logoCara Therapeutics, Inc. (NASDAQ:CARA) CEO Sells $376,250.00 in Stock - July 18 at 7:24 PM logoCara Therapeutics, Inc. (CARA) Given Consensus Recommendation of "Buy" by Brokerages - July 18 at 11:35 AM logo3 Stocks to Watch on Wednesday: Square Inc (SQ), Cara Therapeutics Inc (CARA) and Healthcare Services Group, Inc ... - - July 14 at 11:53 PM logoETFs with exposure to CARA Therapeutics, Inc. : July 14, 2017 - July 14 at 6:52 PM logo1 Reason Why Cara Therapeutics Ended June Down 11.3% - Motley Fool - July 13 at 8:33 PM logoUPDATE: Cara Therapeutics shares surge 13.7% premarket on positive trial results - MarketWatch - July 13 at 3:30 PM logoHere's Why Cara Therapeutics Inc. Is on the Rise Today - Motley Fool - July 13 at 3:30 PM logoThis Biotech Popped 7% On Strong Trial Data - July 12 at 10:34 PM logoCara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease - July 12 at 5:33 PM logoThis Marijuana Stock Has Lost More Than Half Its Value in 2 Weeks - July 12 at 5:33 PM logoUPDATE: Cara Therapeutics shares surge 13.7% premarket on positive trial results - July 12 at 5:33 PM logoHere's Why Cara Therapeutics Inc. Is on the Rise Today - July 12 at 5:33 PM logoWhy This Biotech Could Be Poised For A Run After Toppling 52% In June - July 12 at 5:33 PM logoForm SC 13G/A Cara Therapeutics, Inc. Filed by: STATE STREET CORP - - July 11 at 5:57 PM logoCan Cara Therapeutics Stock Bounce Back? - Motley Fool - July 11 at 5:57 PM logoCan Cara Therapeutics Stock Bounce Back? - July 11 at 5:57 PM logoHere's Why Nobody's Itching to Buy Cara Therapeutics Stock Today - Motley Fool - July 10 at 4:54 PM logoToday's Research Reports on Stocks to Watch: Cara Therapeutics and Threshold Pharmaceuticals - July 10 at 4:54 PM logoHere's Why Nobody's Itching to Buy Cara Therapeutics Stock Today - July 10 at 4:54 PM logoCara Therapeutics' New Pain Drug Still Has Value After Failed Clinical Trial - July 6 at 6:10 PM logoUp in Smoke: Here's Why This Marijuana Stock Absolutely Imploded Last Week - July 5 at 5:39 PM logoCara Therapeutics, Inc. (NASDAQ:CARA) Receives "Positive" Rating from Canaccord Genuity - July 5 at 9:50 AM logoCARA Therapeutics, Inc. – Value Analysis (NASDAQ:CARA) : July 4, 2017 - July 4 at 9:29 PM logoCara Therapeutics, Inc. (CARA) Director Dean Slagel Sells 250,000 Shares - July 3 at 7:28 PM logoPiper Jaffray Companies Analysts Give Cara Therapeutics, Inc. (CARA) a $27.00 Price Target - July 3 at 7:02 PM logoCanaccord Genuity Analysts Give Cara Therapeutics, Inc. (NASDAQ:CARA) a $25.00 Price Target - July 3 at 6:25 PM logoCara Therapeutics Inc. (CARA) Sank On Phase 2 Study Results - July 3 at 4:59 PM logoCARA Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CARA-US : July 3, 2017 - July 3 at 4:59 PM logoAnalyst keeps Buy rating for Cara Therapeutics despite trial disappointment - Seeking Alpha - July 1 at 9:43 PM logoCara Therapeutics (CARA) Updates On CR845-CLIN2002 OA Phase 2b Data - Slideshow - July 1 at 4:41 PM logoCara Therapeutics (CARA) Updates On CR845-CLIN2002 OA Phase 2b Data - Slideshow - July 1 at 4:41 PM logoCara Therapeutics' stock plunges after mixed trial results prompts analyst downgrade - July 1 at 4:41 PM logoCara Therapeutics' stock plunges after mixed trial results prompts analyst downgrade - July 1 at 4:41 PM logoCara Therapeutics Stock Crashes on Mixed Clinical Results (CARA) - July 1 at 4:41 PM logoCara Therapeutics Stock Crashes on Mixed Clinical Results (CARA) - July 1 at 4:41 PM logoCara Therapeutics Stock Crashes on Mixed Clinical Results - July 1 at 4:41 PM logoCara Therapeutics Stock Crashes on Mixed Clinical Results - July 1 at 4:41 PM logoHere's Why Cara Therapeutics (CARA) Shares Plummeted 31% Today - July 1 at 4:41 PM logoHere's Why Cara Therapeutics (CARA) Shares Plummeted 31% Today - July 1 at 4:41 PM logoCara Therapeutics, Inc. (NASDAQ:CARA) Lowered to "Neutral" at Janney Montgomery Scott - July 1 at 11:20 AM logoCara Therapeutics, Inc. (NASDAQ:CARA) PT Lowered to $30.00 at Laidlaw - July 1 at 10:40 AM logoCara Therapeutics Nose-Dives After Trial Disappoints -- What Now? - Motley Fool - June 30 at 10:04 PM logoCara Therapeutics' (NASDAQ:CARA) "Buy" Rating Reiterated at Needham & Company LLC - June 30 at 7:12 PM logoCara Therapeutics, Inc. (NASDAQ:CARA) Rating Reiterated by HC Wainwright - June 30 at 7:12 PM logoMid-Afternoon Market Update: Crude Oil Up 2.5%; Cara Therapeutics Shares Slide - Nasdaq - June 30 at 5:01 PM logoWhy Cara Therapeutics Stock Is Crashing - Motley Fool - June 30 at 5:01 PM logoBiotech Plunges 40% On Mixed Trial — Is There A Silver Lining? - June 30 at 5:01 PM logoCara Therapeutics, Inc. (CARA) Price Target Cut to $20.00 by Analysts at Stifel Nicolaus - June 30 at 9:29 AM logoCara Therapeutics (CARA) Reports Results from Phase 2b Trial of Oral CR845 in Chronic Pain - June 30 at 4:07 AM



Cara Therapeutics (CARA) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by Staff